83 related articles for article (PubMed ID: 21475131)
1. Current dilemmas in carboplatin dosing.
Ratain MJ
Clin Adv Hematol Oncol; 2011 Mar; 9(3):237-8. PubMed ID: 21475131
[No Abstract] [Full Text] [Related]
2. [Determination of individual kidney function?].
Lipp HP
Med Monatsschr Pharm; 2008 Oct; 31(10):393-5. PubMed ID: 18975414
[No Abstract] [Full Text] [Related]
3. Carboplatin dosing in children: calculation by different formulae.
Würthwein G; Krefeld B; Gerss J; Boos J
Onkologie; 2011; 34(1-2):16-22. PubMed ID: 21346380
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
de Lemos ML; Hsieh T; Hamata L; Levin A; Swenerton K; Djurdjev O; Vu T; Hu F; Conklin J; Malfair Taylor SC
Gynecol Oncol; 2006 Dec; 103(3):1063-9. PubMed ID: 16875719
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin dosing accounting for the renal and hematologic status of patients.
Busse T
Clin J Oncol Nurs; 2003; 7(1):104-5. PubMed ID: 12629944
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin.
Jennings S; de Lemos ML; Levin A; Murray N
J Oncol Pharm Pract; 2010 Jun; 16(2):113-9. PubMed ID: 19578094
[TBL] [Abstract][Full Text] [Related]
7. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer.
Donadio C; Lucchesi A; Ardini M; Cosio S; Fanucchi A; Gadducci A
Ther Drug Monit; 2009 Feb; 31(1):63-9. PubMed ID: 19077927
[TBL] [Abstract][Full Text] [Related]
8. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
[TBL] [Abstract][Full Text] [Related]
9. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
[TBL] [Abstract][Full Text] [Related]
12. Reply to the letter to the editor 'Measured and estimated glomerular filtration rate for carboplatin dose calculation' by Cathomas et al.
Bertelli G; Quinton AE; Lewis PD; Ali P; Morgan C
Ann Oncol; 2015 Jan; 26(1):249-250. PubMed ID: 25319063
[No Abstract] [Full Text] [Related]
13. Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies.
Calvert AH; Egorin MJ
Eur J Cancer; 2002 Jan; 38(1):11-6. PubMed ID: 11750834
[No Abstract] [Full Text] [Related]
14. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy.
Veal GJ; English MW; Grundy RG; Shakespeare C; Glaser A; Waters F; Holden V; O'Meara A; Michalski A; Howe K; Cole S; Boddy AV
Cancer Chemother Pharmacol; 2004 Oct; 54(4):295-300. PubMed ID: 15133627
[TBL] [Abstract][Full Text] [Related]
15. Investigating current practices in renal function measurement and carboplatin dosing in children with cancer - a UK perspective.
Roberts E; Mogg JAW; Barnfield M; Veal GJ
Pediatr Hematol Oncol; 2020 Apr; 37(3):235-244. PubMed ID: 31941404
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin's fourth decade: still searching for its sweet spot.
Quinn DI
Ann Oncol; 2014 Aug; 25(8):1457-8. PubMed ID: 24950978
[No Abstract] [Full Text] [Related]
17. Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Minami H; Ando Y; Saka H; Shimokata K
J Natl Cancer Inst; 1997 Jul; 89(13):968-70. PubMed ID: 9214677
[No Abstract] [Full Text] [Related]
18. Estimating the correct way of calculating the carboplatin dose.
Sierra-Sánchez JF; González-Carrascosa T
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1479-80; author reply 1481-2. PubMed ID: 21424558
[No Abstract] [Full Text] [Related]
19. Use of daily low-dose carboplatin in radiotherapy for non-small cell lung cancer.
Satoh H; Ohara K; Fuji H; Ishikawa H; Yamashita YT; Kamma H; Ohtsuka M; Hasegawa S
Anticancer Res; 1998; 18(6B):4625-7. PubMed ID: 9891530
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin desensitization.
Keat K; Harnett P; Fulcher DA
Ann Allergy Asthma Immunol; 2007 Nov; 99(5):468-9. PubMed ID: 18051220
[No Abstract] [Full Text] [Related]
[Next] [New Search]
